DOW JONES23,719.37+285.80 1.22%
S&P 5002,789.82+39.84 1.45%
NASDAQ8,153.58+62.67 0.77%

Guggenheim Securities Initiates Coverage On Revolution Medicines with Buy Rating, Announces $50 Price Target

Guggenheim Securities analyst Michael Schmidt initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and a $50 price target.

Benzinga · 03/09/2020 10:40

Guggenheim Securities analyst Michael Schmidt initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and a $50 price target.